Six patents currently held, every record listed here
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jan 2034. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jan 2034
Next term end
3
Patent families
When these terms end
Each bar runs from grant to computed term end. 2017 to 2037.20212025202920332037
Every computed term in this portfolio is shown above.Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Oct 2034 · High confidence
Also notable
Ends Jan 2034 · High confidence
Also notable
Ends Oct 2037 · High confidence
Spray Dry Formulations
US 9,925,184
The most cited patent in this portfolio, cited by 19 later US patents, top 25% of utility patents granted in 2018 in our data. Protection runs to 2034.
Non-Selective Kinase Inhibitors
US 10,246,438
Granted 2019 and renewed at 2 of 3 maintenance windows. Protection runs to 2034.
Combination Therapy for Treating Pulmonary Hypertension
US 10,231,966
Granted 2019 and renewed at 2 of 3 maintenance windows. Protection runs to 2037.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jul 14, 2027The maintenance fee for Non-Selective Kinase Inhibitors (US 10,532,994) comes due Jul 14, 2027. Unpaid by Jan 14, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Non-Selective Kinase Inhibitors | 3 in force | to Jan 2034 |
| Combination Therapy for Treating Pulmonary Hypertension | 2 in force | to Oct 2037 |
| Spray Dry Formulations | 1 in force | to Oct 2034 |
Patents held now
Soonest term end first.
Showing 1 to 6 of 6
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,815,815 | Non-Selective Kinase Inhibitors held by Gilead Sciences, Inc. In force · High confidence | In force | High confidence | |
| US 10,246,438 | Non-Selective Kinase Inhibitors held by Pulmokine Inc.; Gilead Sciences, Inc. and Gilead Sciences, Inc. In force · High confidence | In force | High confidence | |
| US 10,532,994 | Non-Selective Kinase Inhibitors held by Gilead Sciences, Inc. In force · High confidence | In force | High confidence | |
| US 9,925,184 | Spray Dry Formulations held by Gilead Sciences, Inc. and Pulmokine, Inc. In force · High confidence | In force | High confidence | |
| US 10,231,966 | Combination Therapy for Treating Pulmonary Hypertension In force · High confidence | In force | High confidence | |
| US 11,364,238 | Combination Therapy for Treating Pulmonary Hypertension In force · Low confidence | In force | Low confidence |
Also on record, not counted in the 6: 5 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.